168 related articles for article (PubMed ID: 23242659)
1. Effect of metabolic syndrome risk factors and MMP-2 genetic variations on circulating MMP-2 levels in childhood obesity.
Belo VA; Luizon MR; Carneiro PC; Gomes VA; Lacchini R; Lanna CM; Souza-Costa DC; Tanus-Santos JE
Mol Biol Rep; 2013 Mar; 40(3):2697-704. PubMed ID: 23242659
[TBL] [Abstract][Full Text] [Related]
2. The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity.
Belo VA; Luizon MR; Lacchini R; Miranda JA; Lanna CM; Souza-Costa DC; Tanus-Santos JE
Int J Obes (Lond); 2015 Jan; 39(1):130-5. PubMed ID: 24100423
[TBL] [Abstract][Full Text] [Related]
3. Plasma matrix metalloproteinase-9 levels, MMP-9 gene haplotypes, and cardiovascular risk in obese subjects.
Luizon MR; Belo VA; Fernandes KS; Andrade VL; Tanus-Santos JE; Sandrim VC
Mol Biol Rep; 2016 Jun; 43(6):463-71. PubMed ID: 27146834
[TBL] [Abstract][Full Text] [Related]
4. The rs243866/243865 polymorphisms in MMP-2 gene and the relationship with BP control in obese resistant hypertensive subjects.
Ritter AMV; de Faria AP; Barbaro NR; Sabbatini AR; Corrêa NB; Brunelli V; Fattori A; Amorim R; Modolo R; Moreno H
Gene; 2018 Mar; 646():129-135. PubMed ID: 29288728
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase (MMP)-2 gene polymorphisms affect circulating MMP-2 levels in patients with migraine with aura.
Gonçalves FM; Martins-Oliveira A; Lacchini R; Belo VA; Speciali JG; Dach F; Tanus-Santos JE
Gene; 2013 Jan; 512(1):35-40. PubMed ID: 23043936
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-2 -735C/T polymorphism is associated with resistant hypertension in a specialized outpatient clinic in Brazil.
Sabbatini AR; Barbaro NR; de Faria AP; Ritter AMV; Modolo R; Correa NB; Brunelli V; Pinho C; Fontana V; Moreno H
Gene; 2017 Jul; 620():23-29. PubMed ID: 28390988
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase-9 genetic variations affect MMP-9 levels in obese children.
Belo VA; Souza-Costa DC; Luizon MR; Lanna CM; Carneiro PC; Izidoro-Toledo TC; Ferraz KC; Tanus-Santos JE
Int J Obes (Lond); 2012 Jan; 36(1):69-75. PubMed ID: 21844877
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney disease.
Marson BP; Lacchini R; Belo V; Dickel S; da Costa BP; Poli de Figueiredo CE; Tanus-Santos JE
Am J Nephrol; 2012; 35(3):209-15. PubMed ID: 22302011
[TBL] [Abstract][Full Text] [Related]
9. A common matrix metalloproteinase (MMP)-2 polymorphism affects plasma MMP-2 levels in subjects environmentally exposed to mercury.
Jacob-Ferreira AL; Lacchini R; Gerlach RF; Passos CJ; Barbosa F; Tanus-Santos JE
Sci Total Environ; 2011 Sep; 409(20):4242-6. PubMed ID: 21794897
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants in matrix metalloproteinase-9 gene modify metalloproteinase-9 levels in black subjects.
Metzger IF; Luizon MR; Lacchini R; Tanus-Santos JE
DNA Cell Biol; 2012 Apr; 31(4):504-10. PubMed ID: 21936677
[TBL] [Abstract][Full Text] [Related]
11. eNOS polymorphism associated with metabolic syndrome in children and adolescents.
Miranda JA; Belo VA; Souza-Costa DC; Lanna CM; Tanus-Santos JE
Mol Cell Biochem; 2013 Jan; 372(1-2):155-60. PubMed ID: 22983816
[TBL] [Abstract][Full Text] [Related]
12. MMP-2 (-1306 C/T) Polymorphism Affects Serum Matrix Metalloproteinase (MMP)-2 Levels and Correlates with Chronic Obstructive Pulmonary Disease Severity: A Case-Control Study of MMP-1 and -2 in a Tunisian Population.
Bchir S; Nasr HB; Anes AB; Benzarti M; Garrouch A; Tabka Z; Chahed K
Mol Diagn Ther; 2016 Dec; 20(6):579-590. PubMed ID: 27412345
[TBL] [Abstract][Full Text] [Related]
13. Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy.
Palei AC; Sandrim VC; Amaral LM; Machado JS; Cavalli RC; Duarte G; Tanus-Santos JE
Exp Mol Pathol; 2012 Apr; 92(2):217-21. PubMed ID: 22327101
[TBL] [Abstract][Full Text] [Related]
14. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases 1, 2, 3 and 9 functional single-nucleotide polymorphisms in idiopathic recurrent spontaneous abortion.
Pereza N; Ostojić S; Volk M; Kapović M; Peterlin B
Reprod Biomed Online; 2012 May; 24(5):567-75. PubMed ID: 22406112
[TBL] [Abstract][Full Text] [Related]
16. Contribution of Matrix Metalloproteinase-2 Genotypes to Taiwan Pterygium Risk.
Hu PS; Hsia NY; Wang ZH; Chen HC; Hsia TC; Lin ML; Wang YC; Chang WS; Bau DT; Tsai CW
In Vivo; 2024; 38(2):539-545. PubMed ID: 38418145
[TBL] [Abstract][Full Text] [Related]
17. Correlations of MMP-2 and MMP-9 gene polymorphisms with the risk of hepatopulmonary syndrome in cirrhotic patients: A case-control study.
Liu JW; Chen DQ
Kaohsiung J Med Sci; 2018 Nov; 34(11):634-642. PubMed ID: 30392570
[TBL] [Abstract][Full Text] [Related]
18. Role of MMP-2, MMP-7, MMP-9 and TIMP-2 in the development of recurrent depressive disorder.
Bobińska K; Szemraj J; Czarny P; Gałecki P
J Affect Disord; 2016 Nov; 205():119-129. PubMed ID: 27434116
[TBL] [Abstract][Full Text] [Related]
19. Higher risk of matrix metalloproteinase (MMP-2, 7, 9) and tissue inhibitor of metalloproteinase (TIMP-2) genetic variants to gallbladder cancer.
Sharma KL; Misra S; Kumar A; Mittal B
Liver Int; 2012 Sep; 32(8):1278-86. PubMed ID: 22621753
[TBL] [Abstract][Full Text] [Related]
20. MMP-2 and MMP-9 gene polymorphisms act as biological indicators for ulinastatin efficacy in patients with severe acute pancreatitis.
Ling L; Li Y; Li H; Li W; Zhang HB
Medicine (Baltimore); 2019 Jun; 98(24):e15831. PubMed ID: 31192912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
